Pharmacological characterization of mare uterus motility with special reference to calcium antagonists and beta-2-adrenergic stimulants.

The research article focuses on study of contractions in the uterus (motility) of mares (female horses), particularly how these contractions are affected by drugs that either block the calcium channels or stimulate beta-2-adrenergic receptors. The result shows that the mare uterus reactions can be substantially inhibited by these drugs, suggesting they could prove an efficient therapeutical alternative in controlling uterine contractions.

Uterine Motility Test In Vitro

• The study began by examining the contractions in the myometrial tissues from both pregnant and non-pregnant mares.
• The spontaneous contractions were not impacted by several different types of drugs, including tetrodotoxin, anticholinergics, antiadrenergics, histamine blockers, antiserotoninergic, and opioid antagonists.
• These contractions could not occur in a medium without calcium and sodium ions, indicating the essential role of these ions in the contraction mechanism of the uterine muscle.

Impact of Beta-2-Adrenergic Stimulants and Calcium Blockers

• Further tests involved the usage of beta-2 adrenergic stimulants (salbutamol and hexoprenaline) and calcium channel blockers (nifedipine and verapamil).
• These compounds were successfully capable of reducing the amplitude of the contractions in the myometrium.
• The half maximal inhibitory concentration (ID50) for salbutamol was found at just 7.7 nM and for nifedipine at 14.6 nM, proving the highly efficient ability these compounds possess in influencing the uterine muscle behavior.

Conclusions and Implications

• The results indicate that the contractility of the mare’s uterus is highly sensitive to both beta-2 mimetic compounds and calcium antagonists.
• This likely implicates that these drugs could be employed therapeutically in order to regulate and control abnormal uterus contractions.
• Particularly, the drug nifedipine is mentioned as a promising alternative to beta-2 stimulants for use in tocolytic therapy, typically administered to suppress premature labor.